Arteritis News and Research

RSS

Sinusitis tied to elevated rheumatic disease risk

The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, particularly in the 5 to 10 years preceding the start of symptoms, finds research published in the open access journal RMD Open.

27 Feb 2024

Clinical insights into hypertension following unilateral adrenalectomy

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Patients who undergo adrenalectomy for unilateral primary aldosteronism (PA) may still develop post-surgery hypertension; however, the clinical characteristics and etiology of patients developing recurrent hypertension after adrenalectomy are unclear.

19 Feb 2024

Scientists achieve breakthrough in treating 'neglected' polymyalgia rheumatica

Scientists have found success in treating a 'neglected' inflammatory condition, polymyalgia rheumatica, with a drug that could provide an alternative to steroids for patients.

25 Oct 2023

Novel arterivirus discovered in Amazonian rodents unveiling a potential viral spillover threat

Discovery of a novel arterivirus in Amazonian rodents sheds light on viral communities and raises concerns about potential transmission to humans.

14 May 2023

Study finds recent shingles infection increases the risk of myocardial infarction

Researchers assessed myocardial infarction (MI) risk after zoster infection.

30 Mar 2023

COVID-19 might increase risk of autoimmune diseases

Researchers examined the associations between coronavirus disease 2019 (COVID-19) and incident autoimmune diseases.

31 Jan 2023

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Potential new diagnostic marker for ulcerative colitis discovered

An international research collaboration has discovered a potential new diagnostic marker for ulcerative colitis in a trans-ethnic analysis of Japanese and white patients.

10 Feb 2022

Pregnant women with Takayasu's arteritis may have high prevalence of maternal and fetal complications

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that pregnant women with Takayasu's arteritis, a type of large-vessel vasculitis, appear to have a high prevalence of serious maternal and fetal adverse outcomes.

2 Nov 2021

Severe COVID-19 negatively impacts kidney function in kidney transplant recipients

During her medical school career, third-year student Skylar Nahi has taken advantage of the mentorship and research opportunities available to Feinberg students.

31 Aug 2021

Three new guidelines released for treatment and management of systemic vasculitis

The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.

9 Jul 2021

Virus transmission by dental tools and prevention by antiviral agent

Researchers at the University of Ljubljana have demonstrated how a virus can spread by droplets during ultrasonic scaler (USS) operation and how this spread can be mitigated by merely substituting the irrigant with clinical virucidal agents, namely sodium hypochlorite and EOW (Electrolyzed Oxidizing Water).

16 Feb 2021

Study uncovers genetic risks of Takayasu arteritis

In a paper published today in the American Journal of Human Genetics, a group of international collaborators led by researchers from the University of Pittsburgh School of Medicine identified new genetic associations that can predict individual susceptibility to a rare inflammatory disease called Takayasu arteritis.

11 Dec 2020

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

Study reveals complex immunology behind MIS-C in children with COVID-19

In a recent paper published in the prestigious journal Cell, researchers from Sweden and Italy show that inflammatory response in Multisystem Inflammatory Syndrome in Children associated with coronavirus disease (COVID-19) differs from the cytokine storm found in severe acute illness, involving autoantibodies at the same time and sharing several features with Kawasaki disease.

8 Sep 2020

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease released

The American College of Rheumatology and the European League Against Rheumatism released the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease. It is the first criteria developed specifically for this recently recognized disease.

4 Dec 2019

Gadolinium-enhanced MRI of shoulders helps predict recurrence of polymyalgia rheumatica

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.

11 Nov 2019

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis.

26 Sep 2019

Oral steroid use in patients with inflammatory diseases increases risk of infection

Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses, found a study in CMAJ.

24 Jun 2019